[go: up one dir, main page]

MX9605660A - Formulaciones liquidas orales de alendronato. - Google Patents

Formulaciones liquidas orales de alendronato.

Info

Publication number
MX9605660A
MX9605660A MX9605660A MX9605660A MX9605660A MX 9605660 A MX9605660 A MX 9605660A MX 9605660 A MX9605660 A MX 9605660A MX 9605660 A MX9605660 A MX 9605660A MX 9605660 A MX9605660 A MX 9605660A
Authority
MX
Mexico
Prior art keywords
oral liquid
alendronate
alendronate formulations
formulations
liquid alendronate
Prior art date
Application number
MX9605660A
Other languages
English (en)
Other versions
MXPA96005660A (es
Inventor
Gerald S Brenner
Ashok V Katdare
Denise Pretzer
Donna T Whiteford
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MXPA96005660A publication Critical patent/MXPA96005660A/es
Publication of MX9605660A publication Critical patent/MX9605660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe un protocolo de terapia para tratar y para evitar el deteriorooseo en pacientes que tienen dificultad para deglutir, por medio de administrar una formulacion líquida de alendronato que se puede diglutir fácilmente. También se describen formas farmacéuticamente de dosis de un jarabe, una solucion acuosa, una solucion formada de un polvo reconstituido, de alendronato, para llevar a cabo el método terapéutico.
MX9605660A 1994-05-17 1995-05-12 Formulaciones liquidas orales de alendronato. MX9605660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/245,289 US5462932A (en) 1994-05-17 1994-05-17 Oral liquid alendronate formulations
US08245289 1994-05-17
PCT/US1995/005926 WO1995031203A1 (en) 1994-05-17 1995-05-12 Oral liquid alendronate formulations

Publications (2)

Publication Number Publication Date
MXPA96005660A MXPA96005660A (es) 1998-02-01
MX9605660A true MX9605660A (es) 1998-02-28

Family

ID=22926074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605660A MX9605660A (es) 1994-05-17 1995-05-12 Formulaciones liquidas orales de alendronato.

Country Status (33)

Country Link
US (1) US5462932A (es)
EP (1) EP0759757B1 (es)
JP (1) JP4111536B2 (es)
KR (1) KR100372966B1 (es)
CN (1) CN1079672C (es)
AT (1) ATE222495T1 (es)
AU (1) AU691634B2 (es)
CA (1) CA2190148C (es)
CO (1) CO4600739A1 (es)
CY (1) CY2336B1 (es)
CZ (1) CZ285860B6 (es)
DE (1) DE69527842T2 (es)
DK (1) DK0759757T3 (es)
DZ (1) DZ1884A1 (es)
ES (1) ES2180646T3 (es)
FI (1) FI118296B (es)
HR (1) HRP950293B1 (es)
HU (1) HU220626B1 (es)
IL (1) IL113651A (es)
MX (1) MX9605660A (es)
MY (1) MY112285A (es)
NO (1) NO310179B1 (es)
NZ (1) NZ289231A (es)
PL (1) PL179634B1 (es)
PT (1) PT759757E (es)
RU (1) RU2176507C2 (es)
SI (1) SI0759757T1 (es)
SK (1) SK281098B6 (es)
TW (1) TW402501B (es)
UA (1) UA29505C2 (es)
WO (1) WO1995031203A1 (es)
YU (1) YU49354B (es)
ZA (1) ZA953960B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
KR19980702210A (ko) * 1995-02-17 1998-07-15 폴락 돈나 엘 비척추골 골절의 위험률을 감소시키는 방법
CA2219354A1 (en) * 1995-05-12 1996-11-14 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US6100301A (en) * 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
CA2267370A1 (en) * 1996-10-04 1998-04-09 Maneesh J. Nerurkar Liquid alendronate formulations
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
GB9802617D0 (en) * 1998-02-07 1998-04-01 Knoll Ag Pharmaceutical formulation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
EP1188441A4 (en) * 1999-06-02 2004-01-28 Procter & Gamble ORAL PREPARATIONS OF DINATRIUM ETIDRONATE
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
HUP0303700A3 (en) 2000-07-17 2006-07-28 Astellas Pharma Inc Chuo Ku Pharmaceutical composition improved in peroral absorbability
WO2002058708A1 (en) * 2001-01-23 2002-08-01 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US7537622B2 (en) * 2001-10-10 2009-05-26 Fmi Newcoal, Inc. Process for drying coal
US7695535B2 (en) 2001-10-10 2010-04-13 River Basin Energy, Inc. Process for in-situ passivation of partially-dried coal
US8197561B2 (en) 2001-10-10 2012-06-12 River Basin Energy, Inc. Process for drying coal
AU2002346583A1 (en) * 2001-12-13 2003-06-30 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
EP1455796A1 (en) * 2001-12-21 2004-09-15 The Procter & Gamble Company Method for the treatment of bone disorders
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
ITTO20020406A1 (it) * 2002-05-13 2003-11-13 Chiesi Farma Spa Formulazioni di bisfosfonati ad uso iniettabile.
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
GR1004331B (el) * 2002-10-07 2003-09-05 Verisfield (Uk) Ltd Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
EP1790347B1 (en) * 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG High dose ibandronate formulation
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
CN1956706A (zh) * 2004-05-24 2007-05-02 宝洁公司 包含一种螯合剂的双膦酸酯肠溶固体口服剂型
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
EP1761270A1 (en) * 2004-06-23 2007-03-14 Merck & Co., Inc. Estrogen receptor modulators
WO2006019843A1 (en) * 2004-07-15 2006-02-23 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
SI1894557T1 (sl) * 2006-09-04 2011-04-29 Gador Sa Tekoči sestavek za preprečevanje in/ali zdravljenje različnih kostnih metabolnih bolezni, uporaba le-tega, ter postopek za pripravo le-tega
EP2086330A4 (en) * 2006-11-21 2010-10-20 Teikoku Pharma Usa Inc BIPHOSPHONATE FORMULATIONS FOR INHALING AND METHOD FOR THEIR USE
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
EP2240159A2 (en) * 2008-02-05 2010-10-20 Actavis Group PTC EHF Alendronate formulations, method of making and method of use thereof
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US9057037B2 (en) 2010-04-20 2015-06-16 River Basin Energy, Inc. Post torrefaction biomass pelletization
US8956426B2 (en) 2010-04-20 2015-02-17 River Basin Energy, Inc. Method of drying biomass
US9889225B2 (en) * 2010-08-20 2018-02-13 Kaohsiung Medical University Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate
RU2608724C2 (ru) 2010-12-06 2017-01-23 Эффэрикс Фармасьютикалз Са Стабильные составы шипучего бисфосфоната со свойствами быстрой солюбилизации
CN103070824B (zh) * 2013-01-24 2014-07-16 天津红日药业股份有限公司 一种含有伊班膦酸钠的注射液
EP3054980B1 (en) * 2013-10-08 2019-09-04 InnoPharma, Inc. Aprepitant oral liquid formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
RU2029550C1 (ru) * 1992-03-20 1995-02-27 Светлана Семеновна Родионова Способ коррекции метаболизма костной ткани
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .

Also Published As

Publication number Publication date
FI964593A0 (fi) 1996-11-15
DZ1884A1 (fr) 2002-02-17
AU2901095A (en) 1995-12-05
HRP950293B1 (en) 2003-08-31
YU49354B (sh) 2005-09-19
WO1995031203A1 (en) 1995-11-23
CZ336796A3 (en) 1997-06-11
HU9603162D0 (en) 1997-01-28
PL179634B1 (pl) 2000-10-31
SK281098B6 (sk) 2000-11-07
US5462932A (en) 1995-10-31
KR970703151A (ko) 1997-07-03
UA29505C2 (uk) 2000-11-15
MY112285A (en) 2001-05-31
NZ289231A (en) 1998-04-27
HU220626B1 (hu) 2002-03-28
PL320614A1 (en) 1997-10-13
HRP950293A2 (en) 1997-04-30
NO964864L (no) 1996-11-15
DE69527842D1 (de) 2002-09-26
IL113651A (en) 1999-08-17
FI118296B (fi) 2007-09-28
ATE222495T1 (de) 2002-09-15
NO964864D0 (no) 1996-11-15
SI0759757T1 (en) 2002-12-31
CA2190148C (en) 2006-02-14
IL113651A0 (en) 1995-08-31
FI964593L (fi) 1996-11-15
JP4111536B2 (ja) 2008-07-02
JPH10504020A (ja) 1998-04-14
RU2176507C2 (ru) 2001-12-10
CZ285860B6 (cs) 1999-11-17
KR100372966B1 (ko) 2003-05-12
DK0759757T3 (da) 2002-10-07
AU691634B2 (en) 1998-05-21
YU31795A (sh) 1999-06-15
PT759757E (pt) 2002-11-29
TW402501B (en) 2000-08-21
HK1009245A1 (en) 1999-05-28
ZA953960B (en) 1996-01-19
CA2190148A1 (en) 1995-11-23
EP0759757A1 (en) 1997-03-05
EP0759757B1 (en) 2002-08-21
CY2336B1 (en) 2004-02-06
HUT76317A (en) 1997-08-28
CO4600739A1 (es) 1998-05-08
SK147796A3 (en) 1997-07-09
DE69527842T2 (de) 2003-04-10
CN1079672C (zh) 2002-02-27
ES2180646T3 (es) 2003-02-16
CN1148341A (zh) 1997-04-23
NO310179B1 (no) 2001-06-05

Similar Documents

Publication Publication Date Title
ZA953960B (en) Oral liquid alendronate formulations
EP1242013A4 (en) ORAL TRANSMUCOSAL GALENIC FORM USING SOLID SOLUTION
NZ503946A (en) Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
CA2390377A1 (en) Method and apparatus for delivery of controlled doses of therapeutic drugs in endoluminal procedures
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
ATE289199T1 (de) Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
EE04330B1 (et) Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks
TW200517119A (en) Method of treatment using interferon-tau
DE69531166D1 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
EG17992A (en) Preparation of a medicament for arthritis and theumatism
RU98118897A (ru) Способ увеличения массы костной ткани при переломах
PT95867A (pt) Processo para a preparacao de uma composicao de libertacao retardada compreendendo um copolimero de lactide e glicolide, para tratamento de doencas periodonticas
UA30251A (uk) Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи